T. Zhuang, S. Goyal, Jacqueline T. Brown, B. Carthon, Omer Kucuk, G. McClintock, L. Yantorni, M. Bilen, V. Master, B. Nazha
{"title":"478 Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI)","authors":"T. Zhuang, S. Goyal, Jacqueline T. Brown, B. Carthon, Omer Kucuk, G. McClintock, L. Yantorni, M. Bilen, V. Master, B. Nazha","doi":"10.1136/jitc-2022-sitc2022.0478","DOIUrl":null,"url":null,"abstract":"Background Penile squamous cell carcinoma (pSCC) is a rare and aggressive neoplasm with poor outcomes in advanced set-tings and limited treatment options beyond TIP chemotherapy (paclitaxel/ifosfamide/cisplatin). We evaluated real-world outcomes in patients treated with immune checkpoint inhibitors (ICI) for pSCC. Methods We performed a retrospective review of patients with pSCC who received ICI from 2012-2022 at the Winship Cancer Institute at Emory University. Clinical benefit was defined as complete response, partial response, or stable disease based on RECIST 1.1 criteria. Overall survival(OS) and progression-free survival(PFS) were assessed by Kaplan-Meier method and univariate Cox regression(UVA). Results Of 71.4% were","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regular and Young Investigator Award Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jitc-2022-sitc2022.0478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background Penile squamous cell carcinoma (pSCC) is a rare and aggressive neoplasm with poor outcomes in advanced set-tings and limited treatment options beyond TIP chemotherapy (paclitaxel/ifosfamide/cisplatin). We evaluated real-world outcomes in patients treated with immune checkpoint inhibitors (ICI) for pSCC. Methods We performed a retrospective review of patients with pSCC who received ICI from 2012-2022 at the Winship Cancer Institute at Emory University. Clinical benefit was defined as complete response, partial response, or stable disease based on RECIST 1.1 criteria. Overall survival(OS) and progression-free survival(PFS) were assessed by Kaplan-Meier method and univariate Cox regression(UVA). Results Of 71.4% were
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
